Stockreport

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers [Seeking Alpha]

Y-mAbs Therapeutics, Inc.  (YMAB) 
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm Check Earnings Report
PDF Follow Summary Y-mAbs Therapeutics' naxitamab is approved for R/R High-Risk Neuroblastoma, with ongoing trials to expand its use, but the market size is limited. [Read more]